Table 1.
Clinical Characteristics and Treatment of AMI in Taiwan From 1999 to 2008
| Overall N=108 741 | Male N=78 779 | Female N=29 962 | P Value | |
|---|---|---|---|---|
| Age, y (SD) | 66.3 (13.4) | 64.2 (13.5) | 71.9 (11.5) | <0.001 |
| Risk factors, % | ||||
| Hypertension | 64.4 | 59.4 | 77.8 | <0.001 |
| Diabetes mellitus | 37.8 | 32.3 | 52.1 | <0.001 |
| Dyslipidemia | 32.2 | 29.8 | 38.6 | <0.001 |
| Cardiovascular history, % | ||||
| Coronary artery disease | 47.5 | 45.4 | 52.9 | <0.001 |
| Atrial fibrillation | 3.2 | 2.7 | 4.8 | <0.001 |
| Peripheral artery disease | 2.6 | 2.1 | 3.7 | <0.001 |
| Stroke | 11.9 | 10.8 | 14.9 | <0.001 |
| Comorbidity, % | ||||
| Chronic lung disease | 32.2 | 31.3 | 34.6 | <0.001 |
| Chronic renal disease | 18.9 | 16.6 | 24.7 | <0.001 |
| Cancer | 15.5 | 14.9 | 17.2 | <0.001 |
| Peptic ulcers | 22.9 | 21.4 | 26.6 | <0.001 |
| In‐hospital drug use | ||||
| Aspirin | 94.7 | 95.2 | 93.5 | <0.001 |
| Clopidogrel | 63.2 | 63.3 | 62.8 | 0.1 |
| Ticlopidine | 11.4 | 12.0 | 9.7 | <0.001 |
| GP IIbIIa inhibitor | 14.4 | 15.9 | 10.6 | <0.001 |
| DAPT | 64.4 | 65.6 | 61.0 | <0.001 |
| β‐Blocker | 60.0 | 60.5 | 58.5 | <0.001 |
| ACEI or ARB | 73.1 | 73.2 | 72.6 | 0.056 |
| Statin | 33.3 | 33.9 | 31.9 | <0.001 |
| In‐hospital procedure or surgery | ||||
| Ventilator support | 8.0 | 6.8 | 11.1 | <0.001 |
| IABP | 4.8 | 5.1 | 4.3 | <0.001 |
| ECMO | 0.4 | 0.5 | 0.3 | <0.001 |
| PCI | 49.0 | 52.7 | 39.4 | <0.001 |
| CABG | 6.4 | 6.8 | 5.5 | <0.001 |
Data are presented as N (%) or mean values±SD. P value compared with male and female groups using a Student t test or χ2 test. ACEI indicates angiotensin‐converting enzyme inhibitor; AMI, acute myocardial infarction; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; DAPT, dual antiplatelet therapy; ECMO, extracorporeal membrane oxygenation; GP, Glycoprotein; IABP, intra‐aortic balloon pumping; PCI, percutaneous coronary intervention.